Trial Profile

ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2025 According to GSK plc media release, company announced that US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma based on data of this trial.
04 Jun 2024 Results (n=34) assessing data in relapsed and refractory osteosarcoma patients treated with HS-20093 from ARTEMIS-002 study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
19 Jul 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com